Galectin-3 has also been related to lipid content in the liver through interactions with the lipid uptake marker CD36 and PPAR-γ, and ablation of galectin-3 in mice provided a protective effect on non-alcoholic steatohepatitis by reducing liver steatosis [11, 12]. The gene discussed is LGALS3; the disease is metabolic dysfunction-associated steatohepatitis.